India Clears Path for ‘Game-Changing’ HIV Prevention Drug
What Happened
India's drug regulator has granted Dr. Reddy's Laboratories (DRL) and Emcure Pharmaceuticals approvals and waivers from local clinical trials to manufacture lenacapavir, a breakthrough HIV prevention medicine. Lenacapavir is a long-acting injection that needs to be administered only twice a year and has been hailed as a major advance in HIV prevention.
Key Takeaways
With DRL and Emcure now cleared to manufacture the drug locally, India is positioned to play a key role in expanding affordable access to lenacapavir, a potentially transformative HIV prevention treatment that requires just two injections a year.